Mosquito-Borne Viruses of the Midwestern United States

(As if you needed another reason to dislike mosquitoes)

17 June 2020 WCLN Webinar Series

Eric T. Beck, PhD, D(ABMM), MB(ASCP)^{CM}
Technical Director-Microbiology
ACL Laboratories/Advocate Aurora Health



Outline

- Brief overview on mosquito-borne diseases
- Mosquito-borne viruses of the Midwestern United States
 - · Viral Characteristics
 - Mosquito vectors
 - · Primary hosts
 - Symptoms
 - Diagnosis
- Clinically relevant travel-related mosquito-borne viruses
- Overwintering Mechanism
- Summary
- Questions



Mosquito-Borne Diseases

- Worldwide, vector-borne diseases have been estimated to account for >17% of infectious disease burden
- Over 1 billion vector-borne infections each year with the majority being mosquito-borne¹⁻³
 - Malaria 228 million cases in 2018; 405,000 deaths
 - Dengue 100 400 million cases per year; severe disease in less than 1%
- · The US CDC considers the mosquito the deadliest animal in the world



Vector-Borne Disease in WI: 2016 – 2018⁴

- From 2016 2018 WI Averages
 - 110 cases of mosquito-borne infection each year
 - 3200 cases of tick-born infection each year
- Of mosquito-borne infections, viruses account for approximately 80%
 - Remainder are almost exclusively imported malaria cases
 - · Most common locally acquired viruses are
 - West Nile Virus
 - · California Encephalitis Virus
 - · Most common imported viruses are
 - Dengue
 - Zika




California Serogroup Viruses




California Serogroup Viruses

- Family Peribunyaviridae
- · Genus Orthobunyavirus
- Includes:
 - California Encephalitis Virus
 - La Crosse Virus
 - Jamestown Canyon Virus
- Enveloped virion
- Genome
 - Three segments
 - Negative-sense
 - Single stranded RNA




California Serogroup Viruses

- · Traditional life cycle between small mammals and mosquitoes
- Humans are dead end hosts
- Transmitted by a variety of mosquitoes including: Aedes, Ochlerotatus, Culiseta
- May be transmitted from female to her eggs (transovarial transmission)
- Venereal transmission from males to females
- Extrinsic incubation period 7-14 days



La Crosse Encephalitis Virus⁵⁻⁶

- Named for La Crosse, WI
 - Virus identified in 1964 (case from 1960)
- Primary vector: Ochlerotatus triseriatus
- Distribution: Midwestern and Southeastern US
- Incubation Period: 5 15 Days
- · Disease Manifestation:
 - Often asymptomatic
 - Mild disease includes fever, malaise, headache, nausea, vomiting
 - Severe disease includes encephalitis and seizures





La Crosse Encephalitis Virus

- · Epidemiology:
 - · Can infect all age groups
 - · Most common around wooded areas
 - Almost all serious infection occurs in children
 4 years of age
- Mortality rate: < 1 % in patients with encephalitis
- · Annual cases:
 - · Mild infections likely very underreported
 - Neuroinvasive cases approximately 70 per year in US
- Prevention: Mosquito repellent
- · Treatment: Supportive care





La Crosse Encephalitis Virus

- · Immunity: Infection is thought to confer life-long immunity
- Long-Term Issues:
 - Neurologic sequelae include:
 - · Recurrent seizures
 - Cognitive abnormalities
 - Hemiparesis (weakness on one side of body)
 - Medical costs associated with sequelae can range from \$50K \$3M⁷



Jamestown Canyon Virus⁸

- · Discovered in Culiseta mosquitoes in Jamestown, CO in 1961
- Vectors include: Aedes, Ochlerotatus, Culex, and Culiseta sp.
- Primarily found in MN and WI
- Incubation Period: 5 15 Days
- · Disease Manifestation:
 - Often asymptomatic
 - Mild disease includes fever, malaise, headache, mild respiratory symptoms
 - Severe disease includes encephalitis and meningitis



Jamestown Canyon Virus

- Epidemiology:
 - · Can infect all age groups
 - Most common around wooded areas
 - No clear age group at risk
- Mortality rate: < 1 % in patients with encephalitis
- Annual cases:
 - · Mild infections likely very underreported
 - Neuroinvasive cases approximately <50 per year in US



Jamestown Canyon virus neuroinvasive disease



Jamestown Canyon Virus

Prevention: Mosquito repellentTreatment: Supportive care

• Long-Term Issues: Thought to be very rare

• Immunity: Infection is thought to confer life-long immunity




Diagnosis of California Serogroup Viruses




Real-Time RT-PCR

- Reverse Transcriptase Polymerase Chain Reaction
- · Detects the presence of virus
- High specificity
- Virus often only present at detectable levels early during course of infection
- · La Crosse and Jamestown Canyon Assays available
 - · Performed at CDC
 - · Best specimen is usually CSF



IgM Capture ELISA (MAC-ELISA)

- · Detects early immune response to virus
- IgM testing via MAC-ELISA (at WSLH)
 - · Anti-human IgM antibodies conjugated to plate
 - Patient specimen added to capture IgM molecules
 - · Specific virus antigen added
 - Conjugated virus specific IgG antibody used for detection
- Positive result generally indicative of recent infection
- · Many arboviral IgM antibodies are cross reactive



Plaque Reduction Neutralization Test (PRNT)

- Plaque Reduction Neutralization Test (PRNT) performed at CDC
 - · More specific than MAC-ELISA
 - · Prepare serial dilutions of serum
 - · Combine dilutions with standard viral inoculum
 - · Add serum/virus combination to cell monolayer
 - · Remove and overlay cells with agar
 - · Incubate for appropriate timeframe
 - Identify serum titer that reduces viral plaques by 50%




Mosquito-Borne Flaviviruses of the US



Mosquito-Borne *Flaviviruses*

- · Family Flaviviridae
- · Genus Flavivirus
- · Viruses circulating in the United States include:
 - West Nile virus
 - St. Louis Encephalitis
- Other common mosquito-borne Flaviviruses:
 - · Japanese encephalitis virus
 - Dengue virus
 - · Yellow fever virus
- Viral properties:
 - Enveloped
 - Non-segmented, positive sense, single stranded RNA genome








Mosquito-Borne *Flaviviruses*

- · Endemic in the United States:
 - West Nile Virus
 - · St. Louis Encephalitis virus
- Traditional life cycle between birds and mosquitoes




- · Humans and horses are dead end hosts
- Generally cause asymptomatic or mild febrile illness
- · Neuroinvasive infections are relatively rare



West Nile Virus⁹⁻¹¹

- · First identified in West Nile District of Uganda in 1937
- First US cases identified in New York in 1999
 - Believed to have originated from Israel
 - Unknown if virus entered US in infected birds or mosquitoes
- Cases in 3 states in 2000
- Cases in 45 states by 2003
- Leading mosquito-borne disease in the United States including WI
- · Found in all 50 states



West Nile Fever

- · Occurs in about 25% of cases
- · Affects all ages
- Common symptoms:


headache, fever, myalgia, rash (generally at time of defervescence)

- · Less common symptoms:
 - nausea, joint pain, eye pain
- · Can last days to weeks, with prolonged fatigue



Neuroinvasive West Nile

- Occurs in < 1% of cases
- Disease Manifestation:
 - Meningitis
 - Encephalitis
 - Acute flaccid paralysis
- · Lasts weeks to months
- Long term functional and cognitive difficulties are common
- Mortality rate ~10% in neuroinvasive disease





West Nile Virus

- · Prevention: Mosquito repellent
- · Treatment: Supportive care
- · Vaccine available for horses
- Average 2000-3000 reported cases annually
- · Can be transmitted via blood transfusion
- Minimal transmission possible during pregnancy or breastfeeding



West Nile Virus Diagnosis

- IgM Capture ELISA (MAC-ELISA) or Microsphere Immunoassay (MIA)
 - Generally present by day 8 of disease
 - · Disappears within a few months post infection
 - May be detectable in CSF earlier than blood
 - MIA performed at WSLH
- IgG draw at day 7 and 21 to compare titers
- RT-PCR
 - · CSF or Blood
 - Only useful very early in infection prior to Ab production
 - Sensitivity is very low ~50% in CSF; 10% in blood



St. Louis Encephalitis Virus¹²⁻¹³

- First identified in St. Louis, MO in 1933
- Transmitted primarily by Culex mosquitoes
- · Primarily found in Central and Western states
- Largest US epidemic was in 1975
 - Almost 2000 cases of SLEV neuroinvasive disease
 - Ohio/Mississippi River basin
- Incubations period is 5-15 days
- Less than 1% of cases are clinically apparent disease

Culex sp. mosquitoes – primary vector of SLEV in WI



Neuroinvasive St. Louis Encephalitis Virus

- Abrupt onset:
 - · Fever, headache, dizziness, nausea
- Disease may end or progress to include:
 - Stiff neck, confusion, dizziness, tremors or other signs of CNS disease
- Risk of severe disease increases with age
- · Up to 90% of elderly develop encephalitis
- Case fatality rate of about 10%
- Symptoms can persist for up to three years





St. Louis Encephalitis Virus

- Diagnosis consists of:
- MAC-ELISA or MIA
 - · Performed on serum or CSF
 - IgM present one week after onset; declines rapidly (~ 3 months)
 - IgM positive indicates acute infection
 - · Performed at WSLH
- IgG 4-fold rise in titer between acute and convalescent serum




Mosquito-Borne Alphaviruses of the US




Mosquito-Borne *Alphaviruses*

- Family Togaviridae
- Genus Alphavirus
- · Viruses circulating in the United States include:
 - Eastern Equine Encephalitis Virus
 - Western Equine Encephalitis Virus
- Other common mosquito-borne Alphaviruses:
 - Chikungunya
 - Venezuelan Equine Encephalitis Virus
- Viral properties:
 - Enveloped
 - Non-segmented, positive sense, single stranded RNA genome



Mosquito-Borne Alphaviruses

- · Endemic in the United States:
 - · Eastern and Western Equine encephalitis viruses
- · Traditional life cycle between birds and mosquitoes
- Primary vectors: Culex tarsalis and Culex pipiens mosquitoes
- Humans and horses are dead end hosts
- · Generally cause asymptomatic or mild febrile illness
- · Neuroinvasive infections are relatively rare





Eastern Equine Encephalitis Virus¹⁴⁻¹⁵

- · First human cases in 1938 in Massachusetts
- Maintained in nature between Cs. Melanura and birds
- Aedes, Culex, and Coquilletidia mosquitoes transmit from birds to humans
- · Greater risk for patients:
 - · Under 15 years of age
 - Over 50 years of age
- · Systemic febrile illness
 - · Fever, chills, arthralgia, myalgia
 - · Last 1-2 weeks
 - Generally complete recovery occurs



Eastern Equine Encephalitis Virus Infections

- · Neurologic illness
 - Fever, headache, vomiting, diarrhea, seizures, behavioral changes
- · Average 7 cases reported annually
 - Almost all reported cases are neuroinvasive; systemic cases rarely reported
- · No treatment
- Vaccine available for horses
- Most cases since 1930s occurred in 2019
 - · 34 cases; 35% fatality rate





Western Equine Encephalitis Virus¹⁶

- First isolated from horses in San Joaquin Valley, CA in 1930
- Maintained in nature between *Culex* mosquitoes and birds
- · No reported cases in US since 1994
- Milder than EEEV
- Case fatality rate is < 10%
- · Greater risk for infants and elderly
- · No vaccine or treatment available



Common Travel-Related Mosquito-Borne Viruses



Zika Virus¹⁷

- · Family Flaviviridae; Genus Flavivirus
- Maintained in nature between A. aegypti and humans
 - Possible transmission between mosquitoes and non-human primates
- Low level circulation prior to first reported outbreak in 2007 in Micronesia
- Transmitted via
 - · Mosquito bite
 - Blood transfusion
 - · Congenital transmission
 - · Sexual transmission
- Symptoms generally mild; last < 7 days



Zika Virus

- Congenital infection associated w/ microcephaly
 - Brain and head smaller than expected
 - 6671 cases in Brazil 10/22/15 3/19/16
 - Of 2378 cases investigated 907 linked w/ congenital Zika infection
 - 163 cases on average from 2001 2014
- · Association with Guillain-Barré syndrome
 - · Auto-immune disease body attacks peripheral nervous system
- 1 travel related Zika case in US in 2020
- · 8 locally acquired cases in US territories in 2020



Zika Virus Diagnosis

- Cases have dramatically decreased and testing only recommended on symptomatic pregnant women with recent travel history
- · RT-PCR testing
 - Serum or urine (virus shed in urine longer)
- Serology
 - · IgM can persist for months to years
 - Antibody tests are cross reactive with DENV
 - Must be confirmed by PRNT



Japanese Encephalitis Virus¹⁸⁻¹⁹

- Family Flaviviridae; Genus Flavivirus
- · Leading cause of vaccine preventable encephalitis in Asia
- Maintained in nature between Culex tritaeniorhynchus and pigs and birds
- · Humans are dead-end hosts
- <1% of those infected develop clinical disease
- Incubation time 5-15 days



Japanese Encephalitis Virus

- · Encephalitis Cases:
 - Most common in children <14 years
 - 50K 175K reported cases/year
 - · 30% fatality rate
 - · 30% report neurological sequelae
- Symptoms include:
 - · Parkinsonian syndrome
 - · Acute flaccid paralysis similar to polio has been reported



Japanese Encephalitis Virus

- One of few mosquito-borne viruses with vaccine available
 - · Highly efficacious
 - · 2 dose vaccine series
 - Recommended for US citizens only if long term travel to endemic countries
- Diagnosis
 - IgM Serology from Serum or CSF
 - IgM detectable for 30 90 days post infection
 - Plaque reduction neutralization testing used to confirm positive serological tests
 - · RT-PCR testing may be used in fatal cases



Dengue Virus²⁰⁻²²

- Family Flaviviridae; Genus Flavivirus
- Dengue outbreaks described dating back to the 1600s
- Virus first isolated in 1943-44
- Maintained in nature between A. aegypti and humans
- Nearly half of the world lives in endemic regions; endemic in over 100 countries
- Primarily travel-related infections in US
- · Occasional local transmission seen in Southern US
- 4 Serotypes (DENV-1, -2, -3, and -4)
- 400 million infections annually



Dengue Fever

- Symptoms are sudden onset
 - Fever, eye pain, muscle pain, joint pain, and rash
 - Originally referred to a "break-bone fever"
- Recovery occurs after a few days
- 114 cases reported in the US already in 2020





Dengue Hemorrhagic Fever

- · More common following secondary infection with different serotype
- Progression from Dengue Fever usually evident around time of defervescence
- Transitional Symptoms include:
 - · Severe abdominal pain, vomiting, hypothermia
- Mild hemorrhagic symptoms:
 - · Petechiae, nose bleeds, gum bleeding
- · Severe hemorrhagic symptoms:
 - Vaginal bleeding, vomiting blood, bloody stool, intracranial bleeding
- >20,000 deaths annually worldwide



Dengue Virus Diagnosis

- Molecular diagnosis days 1-7 post infection
- FDA approved NS1 antigen detection tests
 - Detect NS1 protein of DENV
 - Similar timeframe as Molecular tests
- Serologic diagnosis
 - IgM:
 - typically present about 5 days post infection
 - · Persist for approximately 3 months
 - IgG:
 - · Required paired acute and convalescent serum
- · Immunity is lifelong



Yellow Fever Virus²³

- Family Flaviviridae; genus Flavivirus (type virus)
- Transmitted by A. aegypti
- Most infections are asymptomatic
- Mild illness includes:
 - Sudden onset of fever, chills, headache, nausea, vomiting, fatigue
 - Symptoms approve in about a week
- · Severe illness includes:
 - Initial symptoms may appear to resolve briefly
 - · High fever, jaundice, bleeding from eyes, nose, mouth,
 - · Stomach, vomiting blood, shock, organ failure
 - 30-60% mortality



Yellow Fever Virus

- · Primarily circulating in South America and Africa
- · Cases in US are travel related
 - In 1793, over 5% of Philadelphia's population died of yellow fever
 - Began with refugees fleeing yellow fever epidemic in Caribbean
- Treatment is supportive
- Yellow fever virus has a highly efficacious live, attenuated vaccine
- IgM serology
 - Can persist for years
 - Plaque reduction neutralization testing used to confirm positive serological tests
 - · RT-PCR testing may be used in fatal cases



Chikungunya Virus²⁴⁻²⁵

- First recognized as human pathogen after isolation from outbreak of arthritic disease in Tanzania in 1952
- In Kimakonde language translates to "that which bends up"
- · Very little asymptomatic infection
- · Chikungunya fever
 - · Rapid onset fever
 - · Polyarthralgia and arthritis
 - Rash
 - · Myalgia and headache
- Rarely fatal



Chikungunya Virus

- · Recurring musculoskeletal disease affecting peripheral joints
 - · Can last months to years
- Transmitted by A. aegypti
- United States currently has 8 cases in 2020 all travel related
- Last few years in US, typically a few hundred cases annually
- Viral RNA present during first few days of infection, RT-PCR testing available
- Acute and convalescent IgM should be collected (acute may be sufficient if positive)




Viral Survival in Temperate Climates



Orthobunyaviruses

- Includes La Crosse and Jamestown Canyon Viruses
- Generally transmitted by Aedes and Ochlerotatus mosquitoes
 - · Lay eggs in dry environment likely to flood or just above water line
 - · When flooded, the eggs hatch
- · In fall eggs remain dormant through winter
- Many Orthobunyaviruses found in temperate climates can be transmitted from female mosquito to her eggs
- In spring, emergence of infected females from eggs allow viruses to resumes their life cycles



Flaviviruses

- · Zika, Yellow Fever, Dengue viruses
 - · Viruses generally not transmitted transovarially
 - Predominantly transmitted by Aedes aegypti mosquitoes
 - · Aedes mosquitoes survive winter as eggs
 - Winter generally would break any local transmission cycle
- · West Nile and St. Louis Encephalitis viruses
 - · Viruses generally not transmitted transovarially
 - Predominantly transmitted by Culex mosquitoes
 - Culex mosquitoes survive winter as adults
 - · Avoid freezing remaining dormant in sewers, subways, etc.
 - In spring, emergence of infected adults allow viruses to resume their life cycles



Questions



References

- - https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue
- https://apps.who.int/iris/bitstream/handle/10665/111008/WHO_DCO_WHD_2014.1_eng.pdf
- https://www.cdc.gov/ncezid/dvbd/vital-signs/wisconsin.html
- https://www.cdc.gov/lac/index.html
- Harding et al. La Crosse Virus: A scoping review of the global evidence. Epidemiol Inf. 147(e66): 1-13.
- Utz et al. 2003. Economic and social impact of La Crosse encephalitis in Western North Carolina. Am J Trop Med Hyg. 69(5): 509-518.
- https://www.cdc.gov/jamestown-canyon/index.html
- https://www.cdc.gov/westnile/index.html
 Peterson et al. 2013. West Nile Virus: Review of literature. JAMA. 310(3): 308-315. 10.
- Roehrig. 2013. West Nile virus in the United States-A historical perspective. Viruses. 5: 3088-3108.
- 12. https://www.cdc.gov/sle/index.html
- Kopp et al. 2013. Provenance and spread of St. Louis encephalitis virus. MBIO. 4(3): e00322-13.
- 14. 15. https://www.cdc.gov/easternequineencephalitis/index.html
 Lindsey et al. 2018. Eastern equine encephalitis virus in the United States, 2003-2016. Am J Trop Med Hyg. 98(5): 1472-1477.
- Beckham et al. 2015. Encephalitis. In Mandell, Douglas, and Bennett's Principles and Practices of Infectious Diseases. 8th Ed.
- 17. https://www.cdc.gov/zika/index.html
- https://www.cdc.gov/japaneseencephalitis/index.html
- 19. Filgueira et al. 2019. Review of emerging Japanese encephalitis virus: New aspects and concepts about entry into the brain and inter-cellular spreading. Pathogens. 8,111: 1-19.
- https://www.cdc.gov/dengue/index.html
- Dick et al. 2012. Review: The history of dengue outbreaks in the Americas. Am J Trop Med Hyg. 87(4): 584-593.
- 22. Guzman et al. 2016. Dengue Infection. Nat Rev Dis Primers. 2: 1-25.
- https://www.cdc.gov/chikungunya/index.html
- Cunha et al. 2017. Chikungunya virus: clinical aspects and treatment a review. Mem Inst Oswaldo Cruz. 112(8): 523-531

